Page 34 - Roche Hemlibra Non-inhibitors - Product Monograph

35. Riley RR, Witkop MW, Hellman E, Akins S. Haemophilia 2011;17(6):839−45.
36. Roche Release. Available at: https://www.roche.com/media/releases/med-cor-2019-07-09.htm. Accessed on August 17,
2020.
37. Roche. Data on file.
38. Rodriguez Merchan EC. HSS J 2010;6(1):37−42.
39. Schwartz CE et al. Qual Life Res 2018;27(5):1335−45.
40. Scott MJ et al. Haemophilia 2018;00:1−8.
41. Scott MJ, et al. Haemophilia 2019;25:205–212
42. Shapiro AD et al. Pediatrics 2001;108(6):E105.
43. Sheh-Li Chen. Am J Manag Care. 2016;22:S126-S133
44. Skinner M, et al. ISTH 2019; poster presentation PB0698
45. Srivastava A et al. Haemophilia. 2020 Aug;26 Suppl 6:1-158.
46. Srivastava A et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020.
doi:10.1111/hae.14046.
47. St Louis J et al. BMC Hematol 2016;16:13.
48. Tlacuilo Parra A, Villela Rodriguez J, Garibaldi Covarrubias R, et al. Pediatr Blood Cancer 2010;54(3):394−7
49. Valentino LA et al. J Thromb Haemost 2012;10(3):359−67.
50. Victor Jimenez-Yuste et al. Blood 2017; 130 (Supplement 1): 86. doi: https://doi.org/10.1182/blood.V130.Suppl_1.86.86
51. Witkop M et al. Am J Hematol 2015;90:S3−10.
52. World Federation of Hemophilia (WFH). Annual Global Survey 2016. Available at: https://www.wfh.org/en/data-collection.
Accessed on 10 September 2018.
53. Young G, et al. Blood 2019; https://doi.org/10.1182/blood.2019001869
54. Zhou ZY, Koerper MA, Johnson KA, et al. Burden of illness: Direct and indirect costs among persons with hemophilia A in
the United States. J Med Econ 2015;18(6):457−65.

HEMLIBRA Monograph-Non-inhibitors | 32
®